������Ƶ

‍OXFORD, UNITED KINGDOM - 16 SEPTEMBER 2024. ������Ƶ, the private, clinical-stage biopharmaceutical company developing effective, rapid-acting and accessible medicines for people living with mental health conditions, today announced that it will be presenting data on BPL-003, a novel synthetic intranasal formulation of 5-MeO-DMT benzoate, in two poster presentations at the ECNP 2024 Congress in Milan, Italy.��

Dr Chandni Hindocha, Associate Director, Clinical Development at ������Ƶ, will present a poster titled ‘Blinding in psychedelic studies: comparison of placebo and sub-perceptual dose of intranasal 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; BPL-003) in healthy volunteers’ on Sunday 22nd September at 12.35pm - 14.00pm CEST.��

Dr Claire Roberts, VP Head of Clinical Development at ������Ƶ, will present a poster titled ‘Rapid antidepressant effect of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in treatment-resistant patients: a Phase IIa open-label study’ on Monday 23rd September at 12.35pm - 14.00pm CEST.��

BPL-003 is ������Ƶ’s novel synthetic intranasal formulation of 5-MeO-DMT benzoate and is currently under investigation in Phase II studies as a potential therapy for Treatment Resistant Depression and Alcohol Use Disorder. BPL-003 has been specifically designed to overcome some of the challenges of first-generation psychedelics and existing mental health treatments and produce rapid and lasting treatment effects within a short time in clinic of less than 2 hours.��

Speaking on ������Ƶ’s attendance at ECNP, Dr Claire Roberts says: “The ECNP Congress is Europe’s leading scientific meeting for disease-oriented brain research and we are thankful for the opportunity to share data from our clinical studies of BPL-003 with experts in the field. Our poster on blinding in psychedelic studies addresses an important area of psychedelic clinical research and we hope our presentation will be a valuable contribution to this evolving discussion. We are also looking forward to sharing findings from our Phase IIa study of BPL-003 for Treatment Resistant Depression, which will include evidence of the rapid and lasting antidepressant effects of a single dose of BPL-003.”

Initial results from the Phase IIa study of BPL-003 for Treatment Resistant Depression in March 2024 showed that a single 10mg dose of BPL-003 produced a rapid antidepressant response in 55% of patients the day after dosing and this antidepressant effect was durable, with 55% of patients in remission from depression at day 29 and 45% in remission at day 85. BPL-003 also demonstrated a short treatment duration, with subjective effects resolving and patients deemed ready to be discharged by Investigators within an average time of less than 2 hours.��

For more information please contact: Charlotte Chorley, Communications Lead, at info@beckleypsytech.com

About ������Ƶ - ��

������Ƶ Ltd is a private, clinical-stage biopharmaceutical company developing effective, rapid-acting and accessible medicines for people living with mental health conditions. Founded in 2019, and underpinned by more than two decades of pioneering scientific research from the ������Ƶ Foundation, ������Ƶ combines world-leading psychedelic science with extensive drug development expertise in order to optimise patient outcomes, improve treatment opportunities and ease the burden mental health conditions have on individuals, healthcare systems and society. The company’s lead compound, BPL-003, is a novel, synthetic 5-MeO-DMT benzoate formulation currently under investigation in Phase II studies as a potential therapy for Treatment Resistant Depression (TRD) and Alcohol Use Disorder (AUD). BPL-003 is covered by granted US, UK and European composition of matter patents, with multiple further claims pending in various jurisdictions. ������Ƶ’s second clinical-stage asset, ELE-101, is a proprietary intravenous formulation of psilocin benzoate currently being developed as a potential treatment for Major Depressive Disorder (MDD).

‍